As efforts to develop new pre-clinical and clinical inhibitors of the PI3K pathway are ongoing, few PI3K targeting drugs are under clinical evaluation for the treatment of acute lymphoblastic leukemia (Table 3). This evidence concerns the gene PIK3CA and acute lymphoblastic leukemia.